Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Interleukin-2 receptor-targeted fusion toxin: Began Phase II trial of three dose levels and placebo in 60 patients. Doses will be given three times a week for f

Seragen Inc. (SRGN), Hopkinton, Mass.
Product: Interleukin-2

Read the full 70 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE